The effect of andexanet alfa on the pharmacokinetics and renal clearance of the direct factor Xa inhibitors apixaban, rivaroxaban, edodoxaban and betrixaban

被引：0
|
作者：
Leeds, J. M. [1 ]
Lu, G. [2 ]
Kwok, E. [3 ]
Farmer, J. [3 ]
Castillo, J. [4 ]
Mathur, V [5 ]
Bronson, M. D. [6 ]
Curnutte, J. T. [7 ]
Conley, P. B. [2 ]
机构：
[1] Portola Pharmaceut Inc, DMPK, San Francisco, CA USA
[2] Portola Pharmaceut Inc, Biol, San Francisco, CA USA
[3] Portola Pharmaceut Inc, Clin Operat, San Francisco, CA USA
[4] Portola Pharmaceut Inc, Regulatory Affairs, San Francisco, CA USA
[5] MathurConsulting, Woodside, CA USA
[6] Portola Pharmaceut Inc, Project Management, San Francisco, CA USA
[7] Portola Pharmaceut Inc, Res & Dev, San Francisco, CA USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CA08
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] Factor Xa Inhibitor Antidote, Andexanet Alfa Differentially Reverses the Effects of Apixaban, Betrixaban, Edoxaban and Rivaroxaban
    Fareed, Jawed
    Hoppensteadt, Debra A.
    Jeske, Walter
    Tafur, Alfonso J.
    Zorriasateyn, Kambiz
    Ramacciotti, Eduardo
    Lewis, Bruce
    CIRCULATION, 2019, 140
  • [2] Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban
    Abuan, Irene
    Wong, Kristine H.
    Bolinske, Benjamin
    Hale, Katherine S.
    JOURNAL OF PHARMACY TECHNOLOGY, 2019, 35 (03) : 119 - 125
  • [3] Andexanet alfa for the reversal of factor Xa inhibitors
    Favresse, J.
    Hardy, M.
    van Dievoet, M. A.
    Sennesael, A. L.
    Douxfils, J.
    Samama, C. M.
    Vornicu, O.
    Dincq, A. S.
    Lessire, S.
    Mullier, F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (05) : 387 - 397
  • [4] Andexanet Alfa for Bleeding with Factor Xa Inhibitors
    Tomoda, Haruo
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02): : 191 - 191
  • [5] Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
    Mehrotra, Siddharth
    Hoppensteadt, Debra
    Jeske, Walter
    Siddiqui, Fakiha
    Iqbal, Omer
    Tafur, Alfonso
    Lewis, Bruce
    Jaradeh, Mark
    Kantarcioglu, Bulent
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [6] Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
    Mehrotra, Siddharth
    Hoppensteadt, Debra
    Jeske, Walter
    Siddiqui, Fakiha
    Iqbal, Omer
    Tafur, Alfonso
    Lewis, Bruce
    Jaradeh, Mark
    Kantarcioglu, Bulent
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [7] Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
    Mehrotra, Siddharth
    Hoppensteadt, Debra
    Jeske, Walter
    Siddiqui, Fakiha
    Iqbal, Omer
    Tafur, Alfonso
    Lewis, Bruce
    Jaradeh, Mark
    Kantarcioglu, Bulent
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [8] Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis
    Mehrotra, Siddharth
    Hoppensteadt, Debra
    Jeske, Walter
    Iqbal, Omer
    Tafur, Alfonso J.
    Lewis, Bruce
    Fareed, Jawed
    BLOOD, 2019, 134
  • [9] Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage
    Frol, Senta
    Oblak, Janja Pretnar
    Sabovic, Miso
    Kermer, Pawel
    CNS DRUGS, 2023, 37 (06) : 477 - 487
  • [10] Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage
    Senta Frol
    Janja Pretnar Oblak
    Mišo Šabovič
    Pawel Kermer
    CNS Drugs, 2023, 37 : 477 - 487
12345